| Literature DB >> 33372722 |
Agathe Dubuisson1,2, Jean-Eudes Fahrner1,2,3, Anne-Gaëlle Goubet1,2, Safae Terrisse1,2, Nicolas Voisin1,2, Charles Bayard1,2, Sebastien Lofek1,2, Damien Drubay1,4,5, Delphine Bredel1,2, Séverine Mouraud1,2, Sandrine Susini1,2, Alexandria Cogdill1,2,6, Lucas Rebuffet1,2, Elise Ballot7,8, Nicolas Jacquelot1,9,10, Vincent Thomas de Montpreville11, Odile Casiraghi12, Camélia Radulescu13, Sophie Ferlicot14, David J Figueroa15, Sapna Yadavilli15, Jeremy D Waight15, Marc Ballas15, Axel Hoos15, Thomas Condamine16, Bastien Parier17, Christophe Gaudillat18, Bertrand Routy19,20, François Ghiringhelli7,8,21, Lisa Derosa1,22, Ingrid Breuskin23, Mathieu Rouanne1,12,24,25, Fabrice André1,26, Cédric Lebacle17, Hervé Baumert1, Marie Wislez27,28, Elie Fadel29, Isabelle Cremer30,31, Laurence Albiges1,22, Birgit Geoerger32, Jean-Yves Scoazec1,12, Yohann Loriot1,22, Guido Kroemer1,33,34,35,36,37, Aurélien Marabelle1,38, Mélodie Bonvalet1,39, Laurence Zitvogel1,2,26,39.
Abstract
Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.Entities:
Keywords: cancer; immune checkpoint inhibitors; immunomonitoring; precision oncology; “in sitro” assay
Mesh：
Year: 2020 PMID： 33372722 PMCID： PMC7799366 DOI： 10.15252/emmm.202012850
Source DB: PubMed Journal: EMBO Mol Med ISSN： 1757-4676 Impact factor: 14.260